| 1 |
31927166 | Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. | 2020 Mar 20 |
1 |
| 2 |
28950297 | A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. | 2017 Nov 1 |
1 |
| 3 |
27457310 | Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. | 2016 Aug |
1 |
| 4 |
24242862 | Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. | 2014 Apr |
1 |
| 5 |
24252850 | The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. | 2014 Jan |
9 |
| 6 |
19854946 | DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1alpha gene locus. | 2010 Jan |
1 |
| 7 |
20479887 | Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. | 2010 May 7 |
3 |
| 8 |
20600630 | Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity. | 2010 Dec |
2 |
| 9 |
14983893 | Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. | 2004 Feb 15 |
4 |